Skip to main content

Genetic testing strategies for neonatal cholestasis in the neonatal intensive care unit

In brief

Exome or genome sequencing found a cause in 33% of NICU cases

In this single-center review of 174 infants with NICU cholestasis, exome or genome sequencing identified causative variants in 23 of 70 tested, compared with 12 of 125 targeted gene panels and 3 of 54 microarrays. Sequencing also diagnosed seven infants whose targeted panels were inconclusive, but differences in testing year may have influenced the results.

Journal
Journal of pediatric gastroenterology and nutrition (Q1)
Published
17 November 2026
Study design
Cohort / observational study
Evidence level
Level 4, Very Low (CEBM 4)
Authors
Alyshah Lakhani, Shivam Joshi, Sarah Balster, Alexander Weymann, Carol J Potter, Bimal P Chaudhari, et al.
PMID
43042718
DOI
10.1002/jpn3.70696

Why clinicians should know about it

  • Picked for Genetics (clinical) (paper of the day, 19 November 2026): Directly compares genomic sequencing yield in neonatal cholestasis

Abstract

OBJECTIVES: Cholestasis in the Neonatal Intensive Care Unit (NICU) has a broad differential diagnosis, including genetic diseases. Advances in next generation sequencing (NGS) have expanded the ability to identify genetic etiologies. Studies evaluating testing strategies, diagnostic yield, and clinical characteristics of those undergoing genetic testing for cholestasis in the NICU are limited. METHODS: We retrospectively studied patients at a single-center Level IV NICU with cholestasis, genetic testing and Hepatology consultation between January 1, 2015, and December 31, 2024. Microarray, targeted gene panel and exome or genome sequencing (ES/GS) results and clinical characteristics of those tested were reviewed. Diagnostic yield was defined as identification of pathogenic variants determined to be causative of cholestasis. Categorical variables were compared using Chi-squared test or Fisher's exact as appropriate. Continuous variables were compared using Wilcoxon rank sum tests or Kruskal-Wallis tests as appropriate. RESULTS: A total of 174 patients were included for analysis. Patients with three modalities of testing had higher peak direct bilirubin and alanine aminotransferase. Diagnostic yield increased by comprehensiveness: microarray 5% (3/54), targeted gene panel 10% (12/125) and ES/GS 33% (23/70). Seven patients with non-diagnostic targeted panels had diagnostic ES/GS. Those with diagnostic ES/GS were younger at Hepatology consultation, had higher peak direct bilirubin and were less likely to have sepsis compared to those with diagnostic targeted panels. CONCLUSIONS: ES/GS demonstrated greater diagnostic yield for cholestasis in the NICU than other modalities. Confounding by year of testing is possible, but differences in yield support preferential use of ES/GS for neonatal cholestasis evaluation.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.